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Abstract 
Background: Chronic obstructive pulmonary disease (COPD) is a chronic and complex respiratory disorder associ-
ated with airflow limitation and increased inflammatory response of the lungs to harmful particles. The purpose of this 
original study was to describe the results and profile of the Shahrekord Prospective Epidemiological Research Studies 
in IrAN (PERSIAN) regarding COPD in southwestern Iran.
Methods: This study of asthma and respiratory diseases is a subcohort of the more extensive cohort study, i.e., 
Shahrekord PERSIAN cohort, a population-based prospective study on people aged 35–70 years in southwestern Iran 
(n = 10,075). The sample size of the subcohort was 8500 people. Annual follow-ups (person-year) of the cohort were 
designed to be conducted up to 2036. The instruments to collect data on various exposures were derived from the 
questionnaires previously developed in extensive multinational studies (occupational exposures, smoking, housing 
status, and fuel consumption, history of respiratory and chronic diseases, comorbidity, etc.). The Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) and the lower limit of normal (LLN) spirometric criteria were used to con-
firm COPD diagnosis.
Results: The response rate was 93.85%. The mean age of the participants was 49.48 ± 9.32; 47.9% were male, and 
52.9% were female; nearly 16% of the population was current smokers; the fuel used by most of the participants for 
heating the house and cooking was gas. The most common comorbidity among participants was dyslipidemia; 30% 
of people have three or more comorbidities. According to GOLD and LLN criteria, the Prevalence of COPD was 3.6% 
and 8.4%, respectively. 4.3% of the participants had a history of chronic lung disease. The group of subjects with COPD 
had higher mean age, fewer years of schooling, a higher percentage of smokers with a smoking history of 10 or more 
pack years. 4.6% of patients had a history of chronic lung disease, 17.6% had a history of asthma in childhood, and 
5.2% had a family history of respiratory and pulmonary diseases.
Conclusion: Epidemiological research is necessary to create an appropriate framework to fight COPD. This frame-
work requires a better description of men and women at risk of developing COPD and describing people with early-
stage illnesses.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a 
complex respiratory disorder that is caused by airflow 
limitation and increased inflammatory response of the 
lungs to harmful particles and gases, which is usually 
progressive and irreversible [1]. According to the World 
Health Organization, COPD is not a single disease but 
is a so-called umbrella disease that covers a wide range 
of pulmonary diseases, including emphysema and bron-
chitis [2]. It affects 6–10% of the world’s population [3] 
and is one of the most important causes of mortality and 
disability across the globe [4]. The burden of COPD has 
risen over time [5], and the current costs associated with 
this disease are remarkable and will increase in the future 
[6, 7].
In a recently published meta-analysis study, the pooled 
Prevalence of COPD was 15.70%. Among all WHO 
regions, the highest prevalence was in the Americas, and 
the lowest was in the Southeast Asia/West Pacific region 
[8]. In Iran, the prevalence of COPD in estimating the 
burden of obstructive pulmonary disease was 8.3% [9]. 
The Prevalence of COPD in Tehran, the capital of Iran, 
was 9.2% [10] and in Isfahan, )neighboring Chaharma-
hal and Bakhtiari Province( was 5.7% [11]. In another 
study in Iran from 5 different geographical areas in Iran 
(north, south, east and center), the overall prevalence of 
COPD was 4.9%, which is the highest province of Ker-
man (13.9%) and then Tehran 4.4%, Ahvaz was 3.8%, 
Mazandaran was 3.7%, and Mashhad was 2.8%, respec-
tively [12].
Despite the significant impact of COPD on health and 
the economy, this chronic disease has not yet drawn 
enough attention from the public healthcare institutes 
and is not known among the general population. One 
possible reason for this significant problem is the lack 
of epidemiological data on the prevalence and risk fac-
tors of COPD in developing countries, especially in Iran. 
According to previous studies, the diagnosis of COPD is 
underreported in Iran [10].
Evidence and epidemiological data on the status and 
progression of COPD in Iran are minimal and contradic-
tory; the methods for examining this disease in various 
studies are different, and there is a paucity of evidence 
about the natural history of the disease. On the other 
hand, inconsistencies in the information on the Preva-
lence of COPD, chronic bronchitis and asthma in the Ira-
nian population may affect the decision made by health 
care system officials, policy-makers and insurance organ-
izations. They may prevent them from taking adequate 
preventive and treatment measures to prevent potential 
severe effects and stupendous costs [13].
Therefore, this longitudinal study was conducted 
to investigate the need for longitudinal observational 
studies on COPD in Chaharmahal and Bakhtiari prov-
ince, southwestern Iran. The province is geographically 
located at approximately 2,153 m above sea level and is 
known as the roof of Iran. The effect of altitude on other 
medical conditions, such as pulmonary hypertension 
and heart failure, has previously been reported, but the 
potential mechanisms proposed for the effect of altitude 
on the Prevalence of COPD are highly contradictory and 
controversial. In the PREPOCOL-PLATINO-BOLD-EPI-
SCAN study, authors claimed that " known risk factors 
were less frequent at high altitude and high altitude had 
no significant influence in COPD prevalence" [14]. In 
contrast, the PREPOCOL study results in five Colombian 
cities and four geographically diverse in Peru showed that 
the Prevalence of COPD increased with increasing alti-
tude [15, 16].
In Iran, especially Chaharmahal and Bakhtiari prov-
ince, no cohort study has yet been conducted to investi-
gate the problems of lack of diagnosis of COPD and the 
need for intervention. Therefore, this work is a futuristic 
cohort study with a 20-year follow-up period in Chaha-
rmahal and Bakhtiari, southwestern Iran, making it pos-
sible to do cross-sectional and longitudinal data analysis.
Materials and methods
The study of asthma and respiratory diseases is a 
subcohort of a more extensive cohort study, i.e., 
Shahrekord Cohort Study (SCS), a population-based pro-
spective study on people aged 35–70 years in southwest-
ern Iran. SCS was designed to serve as one of the centers 
of the  Prospective  Epidemiological  Research  Studies 
in  IrAN (PERSIAN) Cohort (n = 10,075) and is being 
conducted in the southwest of Iran [17]. The sample size 
of the subcohort was 8500 people. This study began in 
November 2015 in Shahrekord and has been scheduled 
to continue until 2036, with a total follow-up of 200,000 
person-years each year (Fig.  1). Details of the protocol 
and the objectives of the Shahrekord PERSIAN cohort 
have already been published [18].
Outcome definition
The primary outcome of this study is COPD, and mortal-
ity from COPD is an airway inflammatory disease. That 
is associated with continuous airflow limitation, which 
is usually progressive and irreversible. The most com-
mon symptoms of COPD are coughing, phlegm produc-
tion and difficulty breathing, which should be considered 
for the clinical diagnosis of the disease [19]. However, 
none of the symptoms is sufficient to make a diagnosis, 
and if there are several additional symptoms and tests 
to diagnose the disease, the likelihood of a diagnosis of 
COPD increases. According to ICD-10, COPD includes 
emphysema and chronic bronchitis. Chronic coughing 
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is usually the first symptom that occurs. Chronic bron-
chitis is defined as a condition of cough and sputum for 
at least three months for two consecutive years during 
the past year. Diagnosis of emphysema is only possible 
by describing the changes in the anatomy of the lung tis-
sue and cannot be considered a disease per se [1, 20]. The 
most common and easiest way to confirm the diagno-
sis of COPD is spirometry. Most studies have only used 
a questionnaire to diagnose COPD, but in this study, 
both instruments were used for the diagnosis of COPD 
(Table1). Data collection methods and exposure variables 
in a subcohort of Shahrekord PERSIAN Cohort were 
reported in Table 1.
A pulmonary function test was conducted by using a 
spirometer (New Spirolab, MIR, Italy, 2015) according to 
the criteria of the American Thoracic Society/European 
Respiratory Society (ATS/ERS). All tests were conducted 
in a quiet room in a sitting position on a comfortable 
chair. The spirometer was calibrated using a syringe 
by trained technicians daily before the study began. 
All participants were informed about all stages in the 
investigation and the pulmonary function test. All steps 
of the spirometry maneuver were performed practically 
by technicians so that the participant could see how to do 
proper inhaling and exhaling. The person was instructed 
to take a deep, full breath and then exhale forcefully. In-
depth and complete inhalation is no less important than 
strong and complete exhalation. Inadequate and incom-
plete inhalation will lead to an insufficient volume of 
exhalation, resulting in a false decrease in forced vital 
capacity values and an increase in the likelihood of a 
restrictive pattern. Pulmonary function tests were con-
ducted in triplicate for each individual with a single and 
acceptable method. By comparing the curves of the three 
pulmonary function tests, the maximal values of FEV1 
(forced expiratory volume in one second) and FEV6 
(forced expiratory volume in 6 second) forced vital capac-
ity (FVC), maximum peak expiratory flow (PEF) in 25%, 
50% and 75% of FVC (PEF25-75), Maximum Ventilatory 
Volume (MVV) were obtained. Spirometry data were 
interpreted according to the ATS/ERS recommendations 
by two respiratory medicine specialists. The pulmonary 
075),Cohort Study (SCS=10PERSIANSample size of Shahrekord
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Fig. 1 Summarizing Person’s Recruitment and Assessment for Iranian Sub Cohort Chronic Obstructive Pulmonary Disease in Southwest of Iran
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function test parameters values were presented as the 
percent of predicted values for the respective age, height, 
and weight [21].
The GOLD criteria (The Global Initiative for Chronic 
Obstructive Lung disease) uses a fixed ratio of forced 
expiratory volume in 1  second (FEV1) over forced vital 
capacity (FVC) < 0.7 for the diagnosis of COPD [22]. 
The post-bronchodilator spirometry was conducted for 
patients with a pre-bronchodilator FEV1/FVC ratio < 80% 
and 15  min after administration of 2 puffs (200  µg) of 
salbutamol via a spacer standard to evaluate the revers-
ibility of the obstruction. We used a pre-bronchodilator 
FEV1/FVC ratio < 0·8 or an FVC < 80% as cutoffs for 
whether or not to do post-bronchodilator spirometry, 
to avoid underestimating FVC, which could result in a 
normal FEV1/FVC ratio. COPD was defined as the pres-
ence of post-bronchodilator FEV1/FVC of less than 70%. 
Although using this fixed ratio is easy and common, but 
the value varies greatly with age and decreases with age, 
thus leading to underestimation in adults under 45 years 
and overestimation in older people [23, 24]. For these 
reasons, the American Thoracic Society (ATS) and the 
European Respiratory Society (ERS) recommends setting 
the cut-off to 5% of normal to avoid potential Misclassifi-
cation [25, 26]. Therefore, in this study, Spirometry data 
were expressed in predicted percentage according to the 
lower limit of normal (LLN), FEV1/FVC ratio < LLN, and 
also according to the GOLD criteria with a constant ratio 
FEV1/FVC < 0.70 and FEV1 < 80%. In addition, COPD 
severity was determined for all participants according 
to the GOLD criteria as follows: Stage 0 (at risk); stage 1 
(mild): FEV1/FVC < 70% and FEV1 ≥ 80%; stage 2 (mod-
erate): FEV1/FVC < 70% and 50% ≤ FEV1 < 80%; stage 
3 (extreme): FEV1/FVC < 70% and 30% ≤ FEV1 < 50%; 
and stage 4 (extremely severe): FEV1/FVC < 70% and 
FEV1 < 30% [1, 27].
Contraindications for the use of spirometry drugs 
included cardiac infarction, pulmonary embolism, diag-
nosed aneurysm, uncontrolled blood pressure over 
140  mmHg, previous surgery on the eyes, ears, brain, 
abdomen and chest, liver, heart or kidney failure, cancer, 
and endocrine disorders).
Definition of exposures
A questionnaire was used to collect information about 
various exposures. After obtaining informed consent, 
complete information about various exposures was col-
lected by experienced interviewers through face-to-face 
interviews. The main Questionnaire used in this study 
was derived from valid questionnaires that had been used 
in multinational studies. The main exposures of COPD 
disease are specifically studied. The Questionnaire also 
addresses the history and current occupational expo-
sures, individual history and habits (smoking, alcohol, 
tobacco smoking and drinking), as well as sedentary time, 
the age at which smoking began and the stages of change 
of readiness to quit smoking in current smokers, fuel 
status for home heating and cooking, housing situation, 
history of contact with animals, exposure to agricultural 
toxins, pesticides and detergents.
Table 1 Data collection methods, exposure variables and tools in a subcohort of Shahrekord PERSIAN cohort
COPD, chronic obstructive pulmonary disease
Data and collection methods Exposure variables
Questionnaires (self-reported) History and current occupational exposures, personal history and habits (smoking, alcohol, tobacco 
smoking and drinking), as well as sedentary time, the age at which smoking began and the stages of 
change of readiness to quit smoking in current smokers, fuel status for home heating and cooking, 
Housing status, history of contact with animals, exposure to agricultural toxins, pesticides and deter-
gents
Medical history including pulmonary diseases, the history of asthma in childhood, respiratory symptoms, 
respiratory infections, chronic illnesses, drug use, family history of respiratory and pulmonary diseases, 
and questions about whether Have you ever had a doctor or other health care professionals diagnose one 
of the following conditions: Chronic bronchitis, emphysema, pulmonary fibrosis and sleep apnea
Comorbidities: Cardiovascular disease (Myocardial Infarction, Cardiac Ischemia, Heart Failure, stroke), 
Hypertension, Type 2 diabetes, Metabolic syndrome, Dyslipidemia, Anxiety, Depression, Renal failure, 
Fatty liver, Musculoskeletal disorders, Pulmonary blood pressure, Gastroesophageal reflux disease 
(GERD), Pulmonary cancer, Pulmonary fibrosis
Clinical examination Blood pressure, Heart rate, Electrocardiogram(EKG), Breathlessness on exertion
Anthropometry indexes Height, Weight, Waist/Hip/Wrist Circumference, Body Components (fat, water, muscle), Bioimpedance
Blood samples Fasting Blood Sugar, Serum Triglyceride, Total cholesterol, Low and High-Density Lipoprotein, Cholesterol
Spirometry Pre- and Post-bronchodilator for diagnosis of COPD
COPD assessment test (CAT) Only COPD and at-risk
Routine data and BioBank Link all variables to Shahrekord PERSIAN cohort Data Base. A biobank that has been designed to store 
blood, nail, hair and urine samples for future research studies.
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All participants were asked questions about medi-
cal history, including pulmonary diseases, the history of 
asthma in childhood, respiratory symptoms, respiratory 
infections, chronic illnesses, drug use, family history of 
respiratory and pulmonary diseases, and questions about 
whether Have you ever had a doctor or other health care 
professionals diagnose one of the following conditions: 
Chronic bronchitis, emphysema, pulmonary fibrosis and 
sleep apnea.
Comorbidities about which the subjects were asked 
questions due to their clinical significance in COPD, 
included cardiovascular disease (myocardial infarction, 
cardiac ischemia, and stroke), hypertension, type 2 diabe-
tes, syndrome metabolic, dyslipidemia, anxiety, depres-
sion, Osteoporosis, fatty liver, Rheumatoid Arthritis, 
pulmonary fibrosis [21].
In terms of smoking, the participants were divided 
into three groups as follows: Non-smokers, i,e., the peo-
ple who never or occasionally smoked (those who have 
not yet smoked or have smoked less than 100 cigarettes 
during their lifetime); current smokers, i.e., the people 
who smoke one or more cigarettes a day; and ex-smok-
ers, i.e., the people who are not currently smokers but 
smoked regularly in the past). Current exposure to ciga-
rette smoke or passive smoking was also considered to 
be smoking-positive given the smoking of other family 
members or colleagues and exposure to parental ciga-
rette smoke in childhood. Other additional variables such 
as anthropometric measurements and laboratory vari-
ables, which have already been published in the SCS pro-
tocol, were also collected [18]. The list of exposures and 
variables of this cohort were reported in Table 1.
Generalizability of cohort (external cohort credibility)
Subcohort COPD was designed for a sample of approx-
imately 8500 people out of 10,075 individuals aged 
35–70  years for 20  years in Chaharmahal and Bakhtiari 
province, southwest of Iran. It seems that since this 
cohort contains a balanced ratio of men and women and 
urban and rural populations, it is likely to represent the 
community.
Results
The response rate was 93.85%. Based on the results, 7978 
people participated in the subcohort COPD, 6388 (80.1%) 
were urban, and 1590 (19.9%) were rural. The mean age 
of the population enrolled in the study was 49.48 (the 
standard deviation (SD), 9.32) years. 47.9% were male 
and 52.9% were female; 94.3% were married; 48.6% were 
of the Ethnicity Fars, and 39.1% were of the Ethnicity 
Lur Bakhtiari; 14.3% of the participants were illiterate, 
and 34.7% of participants were in the 35‐44 age category. 
51.6% of the participants were housewives/unemployed/
retired, and 18.2% were employees (Table 2).
The mean body mass index of the participants was 
27.70% (SD, 4.58); 44.9% of the population had over-
weight (25–30) and 27.4% had obesity (> 30). Nearly 16% 
of the population was current smokers, with a higher 
proportion of men than women (33.3% VS 0.4%). The 
fuel used by most of the participants for heating the 
house and cooking was gas (65.2%) and also, the type 
of kitchen or cooking area for most participants was an 
open kitchen inside the house (74.9%). The most com-
mon comorbidity among participants was dyslipidemia 
(71.9%) and later hypertension (27.1%). 31.7% of partici-
pants had at least one comorbid and 30% of people have 
three or more comorbidities (Table 3).
According to the GOLD criteria, 289 (3.6%) patients 
had COPD, and according to the LLN criteria, 673 (8.4%) 
had COPD. 4.3% of the participants had a history of 
chronic lung disease (asthma, tuberculosis, emphysema, 
and bronchitis), 11.9% had a history of asthma in child-
hood and 3.9% had a family history of respiratory and 
pulmonary diseases and also 13% of the participants had 
a history of chronic cough and of those who had a chronic 
cough, 47.6% had a history of chronic phlegm; 2.7% of 
the participants had Shortness of breath and wheezing. 
47.8% of patients in the mild stage (GOLD I), 40.1% in 
the moderate stage (GOLD II), 9.8% in the severe stage of 
the disease (GOLD III) and 2.4% in the very severe stage 
of the disease (GOLD IV) were located (Table 4).
The group of subjects with COPD had higher mean 
age, fewer years of schooling, a higher percentage of sub-
jects of smokers with a smoking history of 10 or more 
pack years. The fuel used by most of the participants for 
heating the house and cooking was gas (50.9%), and also, 
the type of kitchen or cooking area for most participants 
was an open kitchen inside the house (68.9%). 4.6% of 
patients had a history of chronic lung disease, 17.6% had 
a history of asthma in childhood and 5.2% had a family 
history of respiratory and pulmonary diseases (Table 5).
Discussion
Results of baseline cohort and profile publication are one 
of the most important outcomes after the completion of 
enrollment in cohort studies. This is useful for research-
ers, helps develop research fields and is helpful for health 
care system planners.
COPD is a preventable and curable disease [28]. Pre-
vention of this disease should be taken into account as 
with other non-communicable chronic diseases, such as 
cardiovascular disease and cancer. Epidemiological stud-
ies are necessary to create an appropriate framework for 
fighting COPD. This framework requires a better descrip-
tion of men and women at risk of developing COPD and 
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a description of people with an early-stage illness. This 
framework should also provide a better understanding 
of the risk factors that can be changed through interven-
tions[29]. Subcohort COPD is the first longitudinal pro-
spective study for COPD with population sampling in 
Iran. This study seeks to provide a broad description of 
the characteristics of men and women with COPD and to 
identify other causes of airway obstruction that can lead 
to an outcome. This study provides a unique opportunity 
to advance and consult observations on people with mild 
and unknown illnesses. The inclusion of healthy people 
and patients in the study provided a new opportunity to 
describe and follow a subgroup of the COPD patients 
who had not already been diagnosed, while many of them 
may at risk or have mild COPD that had not previously 
been diagnosed by a doctor or other health care profes-
sionals [30]. Most national estimates of COPD preva-
lence rates have been usually based on the data derived 
from the patients’ self-report questionnaires and without 
an objective measurement of pulmonary function using a 







Age—mean ± SD (years) 49.48 ± 9.32 49.04 ± 9.20 51.25 ± 9.58
 35–44 years 2772 (34.7%) 2326 (36.4%) 446 (28.1%)
 45–54 years 2708 (33.9%) 2185 (34.2%) 523 (32.9%)
 55–64 years 1914 (24%) 1460 (22.9%) 454 (28.6%)
 ≥ 65 584 (7.3%) 416 (6.5%) 167 (10.5%)
Sex
 Men 3824 (47.9%) 3198 (50.1%) 625 (39.3%)
 Female 4154 (52.1%) 3189 (49.9%) 965 (60.7%)
Ethnicity
 Fars 3874 (48.6%) 3721 (58.3%) 152 (9.6%)
 Lur Bakhtiari 3122 (39.1%) 1775 (27.8%) 1347 (84.7%)
 Turk Qashqai 649 (8.1%) 619 (9.7%) 30 (1.9%)
 Other 333 (4.2%) 272 (4.3%) 61 (3.8%)
Number of family members—mean ± SD 4.00 ± 1.29 3.89 ± 1.14 4.45 ± 1.69
Number of family members—n (%)
 1 84 (1.1%) 59 (0.9%) 25 (1.6%)
 2 782 (10%) 617 (9.9%) 165 (10.5%)
 3 1745 (22.3%) 1477 (23.6%) 267 (17%)
 4 or more 5205 (66.6%) 4096 (65.5%) 1109 (70.8%)
Marital status
 Single 137 (1.7%) 112 (1.8%) 25 (1.6%)
 Married 7520 (94.3%) 6074 (95.1%) 1445 (90.9%)
 Widow and divorced 321 (4%) 201 (3.1%) 120 (7.5%)
Education (N years)—mean ± SD 8.95 ± 6.01 10.16 ± 5.69 4.13 ± 2.08
 Illiterate 1142 (14.3%) 593 (9.3%) 549 (34.5%)
 ≤ 5 years 1689 (21.2%) 1120 (17.5%) 569 (35.8%)
 6–8 years 891 (11.2%) 702 (11%) 189 (11.9%)
 9–12 years 2059 (25.8%) 1855 (29%) 203 (12.8%)
 > 12 years 2197 (27.5%) 2117 (33.1%) 80 (5%)
Occupational status
 Employee 1450 (18.2) 1389 (21.7%) 60 (3.8%)
 Farmer/rancher/herder 293 (3.7) 122 (1.9%) 171 (10.8%)
 Carpet weaver/tailor/weaver 311 (3.9) 239 (3.7%) 72 (4.5%)
 Heavy car driver/mechanic and oil change worker 507 (6.4%) 448 (7%) 59 (3.7%)
 Building contractor/worker and builder 470 (5.9%) 311 (4.9%) 159 (10%)
 Housewife/unemployed/retired 4120 (51.6%) 3142 (49.2%) 978 (61.5%)
 Others 827 (10.4%) 736 (11.5%) 91 (5.7%)
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spirometer [10]. This study provides a good opportunity 
to assess the incidence of COPD by mean of both GOLD 
and LLN criteria from spirometry data so that its results 
can be compared with multivariate models of people who 
have not previously been diagnosed with COPD and who 
have COPD on the basis of known risk factors; in fact, 
this study examined the problems due to lack of COPD 
diagnosis and the need for intervention, and provides an 











Weight status 74.16 ± 13.27 78.15 ± 13.26 70.52 ± 12.20 75.49 ± 12.95 68.89 ± 13.27
Body mass index (BMI)—mean (SD) 27.70 ± 4.58 26.62 ± 4.02 28.68 ± 4.83 27.87 ± 4.47 27.00 ± 4.93
 Underweight (BMI < 20)—n (%) 259 (3.3%) 165 (4.4%) 94 (2.3%) 163 (2.6%) 96 (6%)
 Healthy (20–25)—n (%) 1934 (24.4%) 1100 (29.1%) 834 (20.2%) 1447 (22.9%) 487 (30.7%)
 Overweight (25–30)—n (%) 3550 (44.9%) 1813 (48%) 1737 (42%) 2948 (46.6%) 601 (37.9%)
 Obesity (> 30)—n (%) 2171 (27.4%) 699 (18.5%) 1472 (35.6%) 1768 (27.9%) 403 (25.4%)
Smoking status
 Current smoker n (%) yes 1288 (16.1%) 1272 (33.3%) 16 (0.4%) 1078 (16.9%) 210 (13.2%)
 Former smoker n (%) yes 612 (7.7%) 596 (15.6%) 16 (0.4%) 511 (8%) 101 (6.4%)
 Never smoker n (%) yes 6078 (76.2%) 1956 (51.2%) 4122 (99.2%) 4798 (75.1%) 1279 (80.4%)
Pack-years
 1–10 974 (12.2%) 777 (20.3%) 32 (0.8%) 728 (11.4%) 144 (9.1%)
 10–20 583 (7.3%) 712 (18.6%) 0 (0.0%) 587 (9.2%) 100 (6.3%)
 > 20 343 (4.3%) 379 (9.9%) 0 (0.0%) 274 (4.3%) 67 (4.2%)
Fuels used
 Gas 5198 (65.2%) 2519 (65.9%) 2679 (64.5%) 4777 (74.8%) 421 (26.5%)
 Oil/gasoline 1801 (22.6%) 868 (22.7%) 933 (22.5%) 1183 (18.5%) 618 (38.9%)
 Wood/firewood/animal dung 979 (12.3%) 437 (11.4%) 542 (13%) 427 (6.7%) 551 (34.7%)
Cooking area (kitchen type)
 Closed kitchen inside the house 1905 (23.9%) 826 (21.6%) 1079 (26%) 1371 (21.5%) 534 (33.6%)
 Open kitchen inside the house 5979 (74.9%) 2951 (77.2%) 3028 (72.9%) 4951 (77.5%) 1028 (64.7%)
 Outside of the house 94 (1.2%) 47 (1.2%) 47 (1.1%) 66 (1%) 28 (1.8%)
Kitchen ventilation status
 Ventilated 4422 (55.4%) 2277 (59.5%) 2145 (51.6%) 3899 (61%) 522 (32.8%)
 Not ventilated 3556 (44.6%) 1547 (40.5%) 2009 (48.4%) 2488 (39%) 1068 (67.2%)
Comorbidities diseases status
 Cardiovascular disease 523 (6.6%) 306 (8%) 2.7 (5.2%) 429 (6.7%) 94 (5.9%)
 Chronic lung diseases (asthma, tuberculo-
sis, emphysema and bronchitis)
346 (4.3%) 155 (4.1%) 191 (4.6%) 302 (4.7%) 44 (2.8%)
 Hypertension 2125 (27.1%) 1032 (27.6%) 1093 (26.7%) 1753 (28%) 372 (23.6%)
 Diabetes mellitus 955 (12%) 424 (11.5%) 531 (13.1%) 815 (13.2%) 140 (9.2%)
 Dyslipidemia 5610 (71.9%) 2579 (69.3%) 3031 (74.4%) 4451 (70.9%) 1159 (76%)
 Metabolic syndrome 2006 (25.2%) 1660 (30.5%) 846 (20.4%) 1798 (28.3%) 208 (13.1%)
 Anxiety and depression 1346 (16.9%) 353 (9.2%) 993 (23.9%) 1147 (18%) 199 (12.5%)
 Musculoskeletal disorders 3929 (56.5%) 1562 (47.4%) 2367 (64.7%) 3316 (59.7%) 613 (43.8%)
 Rheumatoid arthritis 385 (4.8%) 115 (3%) 270 (6.5%) 318 (5%) 67 (4.2%)
 Osteoporosis 733 (9.2%) 59 (1.5%) 674 (16.2%) 615 (9.6%) 118 (7.4%)
 Fatty liver 1280 (16%) 489 (12.8%) 791 (19%) 1134 (17.8%) 146 (9.2%)
Comorbidities—n (%)
 None 1211 (15.2%) 676 (17.7%) 535 (12.9%) 972 (15.2%) 239 (15%)
 1 2529 (31.7%) 1265 (33.1%) 1264 (30.4%) 1848 (28.9%) 681 (42.8%)
 2 1848 (23.2%) 849 (22.2%) 999 (24%) 1515 (23.7%) 333 (20.9%)
 3 or more 2390 (30%) 1034 (27%) 1356 (32.6%) 2053 (32.1%) 337 (21.2%)
Page 8 of 11Kiani et al. BMC Pulm Med          (2021) 21:105 
opportunity to address the question Will undiagnosed 
COPD be clinically important? COPD is associated with a 
high incidence rate of one or more diseases. Comorbidi-
ties such as cardiovascular disease, musculoskeletal dis-
orders, and metabolic syndrome are common in patients 
with COPD and significantly affect the quality of life of 
the patients, prognosis, and survival [31–34]. Increasing 
knowledge about the prevalence and effects of comor-
bidities in COPD is essential to adopt better interven-
tion strategies and revise primary health care guidelines. 
COPD prognostic indicators currently focus primarily 
on prediction of mortality risk; creating a large COPD 
cohort for primary care and evaluating a wide range 
of outcomes enable us to review existing prognostic 
indicators and, if necessary, to develop new and appro-
priate prognostic indicators to predict other outcomes 
such as exacerbation and recurrence of disease, hospital 
admissions, and hospitalization due to exacerbation of 
respiratory diseases in primary care to be used in primary 
health care [30]. This study is a valuable work concerning 
increasing the longitudinal information and identifying 
the prognostic factors for COPD and the contribution 
of each of these factors to the progression and develop-
ment of the disease due to its similarity to other cohort 
studies conducted around the world in terms of method-
ology, data collection methods and many other distinc-
tive features [29]. Subcohort COPD is a good platform 
for standard research with Access to a database (such 
Table 4 Baseline airway obstruction in the subcohort of COPD and comparison between sex and residence group













Airway obstruction—LLN 673 (8.4%) 345 (9%) 328 (7.9%) 0.039 558 (8.7%) 115 (7.2%) 0.029
Airways obstruction—FR 289 (3.6%) 159 (4.2%) 130 (3.1%) 0.008 243 (3.8%) 46 (2.9%) 0.045
Chronic lung disease (asthma, tuberculosis, emphy-
sema and bronchitis)—n (%)
346 (4.3%) 155 (4.1%) 191 (4.6%) 0.127 302 (4.7%) 44 (2.8%) < 0.0001
History of asthma in childhood—n (%) 949 (11.9%) 511 (13.4%) 438 (10.5%) 0.028 756 (11.8%) 193 (12.1%) 0.098
family history of respiratory and pulmonary 
diseases—n (%)
311 (3.9%) 138 (3.6%) 173 (4.2%) 0.261 251 (3.9%) 60 (3.8%) 0.879
Symptoms
 Chronic cough—n (%) 1038 (13%) 383 (10%) 655 (15.8%) < 0.0001 937 (14.7%) 101 (6.4%) < 0.0001
 Chronic cough with phlegm—n (%) 494 (47.6%) 201 (52.5%) 293 (44.7%) 0.009 444 (47.4%) 50 (49.5%) 0.382
 Shortness of breath and Wheezing—n (%) 217 (2.7%) 75 (2%) 142 (3.4%) < 0.0001 188 (2.9%) 29 (1.8%) 0.007
Pre-bronchodilator spirometry (n = 7978)
 FEV1 (L.)—mean ± SD 2.84 ± 0.79 2.93 ± 0.81 2.76 ± 0.76 < 0.0001 2.92 ± 0.78 2.55 ± 0.74 < 0.0001
 FEV6 (L.)—mean ± SD 2.08 ± 0.86 3.17 ± 0.87 2.99 ± 0.084 < 0.0001 3.16 ± 0.85 2.74 ± 0.80 < 0.0001
 FVC (L)—mean ± SD 3.08 ± 0.86 3.18 ± 0.88 3.00 ± 0.84 < 0.0001 3.17 ± 0.85 2.74 ± 0.80 < 0.0001
 FEV1/FVC—mean ± SD 92.48 ± 7.47 92.43 ± 7.63 92.52 ± 7.32 0.601 92.27 ± 7.45 93.33 ± 7.50 < 0.0001
 FEV1/FEV6—mean ± SD 92.39 ± 7.48 92.60 ± 7.45 92.62 ± 7.32 0.678 92.42 ± 7.36 93.38 ± 7.41 < 0.0001
 PEF (L)—mean ± SD 5.07 ± 2.09 5.28 ± 2.19 4.88 ± 1.96 < 0.0001 5.24 ± 2.12 4.37 ± 1.79 < 0.0001
 MVV (L/min)—mean ± SD 99.67 ± 27.7 102.54 ± 28.3 97.02 ± 26.96 < 0.0001 102.27 ± 27.55 89.37 ± 26.21 < 0.0001
Post-bronchodilator spirometry (n = 761)
 FEV1 (L.)—mean ± SD 3.23 ± 0.21 3.41 ± 0.74 2.98 ± 0.88 < 0.0001 3.35 ± 0.42 2.78 ± 0.81 < 0.0001
 FEV6 (L.)—mean ± SD 2.51 ± 0.74 3.67 ± 0.84 3.12 ± 0.36 < 0.0001 3.41 ± 0.65 2.98 ± 0.63 < 0.0001
 FVC (L)—mean ± SD 3.89 ± 0.48 3.91 ± 0.73 3.84 ± 0.61 < 0.0001 3.99 ± 0.53 2.93 ± 0.61 < 0.0001
 FEV1/FVC—mean ± SD 91.28 ± 6.94 91.40 ± 6.86 91.62 ± 6.82 0.687 91.39 ± 6.87 92.64 ± 6.91 < 0.0001
 FEV1/FEV6—mean ± SD 92.73 ± 7.21 92.92 ± 7.69 92.89 ± 7.41 0.964 92.68 ± 7.44 93.81 ± 7.48 < 0.0001
 PEF (L)—mean ± SD 5.51 ± 2.32 5.68 ± 2.38 5.21 ± 2.01 < 0.0001 5.84 ± 2.39 4.98 ± 1.94 < 0.0001
 MVV (L/min)—mean ± SD 99.87 ± 28.1 102.66 ± 28.2 98.12 ± 28.91 < 0.0001 102.69 ± 27.97 90.21 ± 27.31 < 0.0001
Severity of COPD
 Mild 138 (47.8%) 92 (55.1%) 46 (37.7%) 0.003 111 (46.8%) 27 (51.9%) 0.801
 Moderate 116 (40.1%) 52 (31.1%) 64 (52.5%) 98 (41.4%) 18 (34.6%)
 Severe 28 (9.8%) 19 (11.4%) 9 (7.4%) 22 (9.3%) 6 (11.5%)
 Very severe 7 (2.4%) 4 (2.4%) 3 (2.5%) 6 (2.5%) 1 (1.9%)
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as lifestyle information, records and occupational expo-
sures, smoking status and exposure to cigarette smoke 
and exposure time, fuel status, medical records, illnesses, 
and outcomes). Reported by patients, housing status and 
lung function test information, etc.). Using linear regres-
sion models with FEV1 as a dependent variable, we can 
Table 5 Baseline behavioral and clinical characteristics of obstructed patients
COPD, chronic obstructive pulmonary disease; LLN, Low limit normal









Weight status, mean (SD) kg 74.17 ± 14.18 74.16 ± 13.24 74.26 ± 13.19 74.15 ± 13.28
Body mass index (BMI)
 Mean (SD) 27.24 ± 4.52 27.71 ± 4.58 27.57 ± 4.56 27.71 ± 4.58
 Underweight (BMI < 20)—n (%) 74 (25.7%) 246 (3.2%) 24 (3.6%) 235 (3.2%)
 Healthy (20–25)—n (%) 130 (45.1%) 1860 (24.4%) 166 (24.9%) 1768 (24.4%)
 Overweight (25–30)—n (%) 71 (24.7%) 3420 (44.8%) 299 (44.8%) 3251 (44.9%)
 Obesity (> 30)—n (%) 75 (26%) 2100 (27.5%) 178 (26.7%) 1993 (27.5%)
Smoking status
 Current smoker 75 (26%) 1213 (15.8%) 159 (23.6%) 1129 (15.5%)
 Ex-smoker 30 (10.4%) 582 (7.6%) 56 (8.3%) 556 (7.6%)
 Never smoker 184 (63.7%) 5894 (76.7%) 458 (68.1%) 5620 (76.9%)
Pack-years
 1–10 51 (17.6%) 1171 (15.2%) 107 (15.9%) 1043 (14.3%)
 10–20 36 (12.4%) 377 (4.9%) 71 (10.5%) 372 (5.1%)
 > 20 18 (6.2%) 247 (3.2%) 37 (5.5%) 270 (3.7%)
Occupational status
 Housewife/unemployed/retired 133 (46%) 3972 (51.7%) 337 (50.1%) 3768 (51.6%)
 Employee 47 (16.3%) 1403 (18.2%) 119 (17.7%) 1331 (18.2%)
 Farmer/rancher/herder 21 (7.3%) 277 (3.6%) 33 (4.9%) 265 (3.6%)
 Carpet weaver/tailor/weaver 12 (4.2%) 301 (3.9%) 25 (3.7%) 288 (3.9%)
 Car driver/mechanic and oil change worker 20 (6.9%) 493 (6.4%) 41 (6.1%) 472 (6.5%)
 Building contractor/worker and builder 24 (8.3%) 448 (5.8%) 45 (6.7%) 427 (5.8%)
 Others 32 (11.1%) 795 (10.3%) 73 (10.8%) 754 (10.3%)
Fuels used
 Gas 147 (50.9%) 5051 (65.7%) 410 (60.9%) 4788 (65.5%)
 Oil/gasoline 88 (30.4%) 1713 (22.3%) 164 (24.4%) 1637 (22.4%)
 Wood/firewood/animal dung 54 (18.7%) 925 (12%) 99 (14.7%) 880 (12%)
Cooking area (kitchen Type)
 Closed kitchen inside the house 82 (28.4%) 1823 (23.7%) 174 (25.9%) 1731 (23.7%)
 Open kitchen inside the house 199 (68.9%) 5780 (75.2%) 483 (71.8%) 5496 (75.2%)
 Outside of the house 8 (2.8%) 86 (1.1%) 16 (2.4%) 78 (1.1%)
Kitchen ventilation status
 Ventilated 149 (51.6%) 4273 (55.6%) 360 (53.5%) 4062 (55.6%)
 Not ventilated 140 (48.4%) 3416 (44.4%) 313 (46.5%) 3243 (44.4%)
Symptoms
 Chronic cough 32 (11.1%) 1006 (14.9%) 79 (11.7%) 958 (14.6%)
 Chronic cough with phlegm 14 (45.2%) 480 (47.7%) 31 (41.9%) 463 (48%)
 Shortness of breath and Wheezing 15 (5.3%) 202 (2.7%) 27 (4.1%) 190 (2.6%)
Chronic lung disease (asthma, tuberculosis, emphysema and 
bronchitis)
13 (4.6%) 333 (4.4%) 27 (4.1%) 319 (4.4%)
History of asthma in childhood 51 (17.6%) 898 (13.3%) 109 (16.1%) 840 (12.8%)
family history of respiratory and pulmonary diseases 15 (5.2%) 296 (4.4%) 39 (5.7%) 272 (4.1%)
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estimate the progression of COPD over time. The data of 
this cohort study provide an appropriate infrastructure 
for the development of mathematical and statistical mod-
els to predict COPD and the survival rate of patients, and 
also the grounds for the analysis of the effects of various 
exposures, smoking and age using regression models and 
mortality rate from COPD as a dependent variable. There 
is a need for research to identify the impact of occupa-
tional exposure in COPD, especially among non-smokers 
by large, prospective and longitudinal studies. Therefore, 
in addition to the impact of occupational exposure, the 
potential interaction between occupational exposure and 
smoking was also addressed in this study. This study also 
provides a basis for answering an important and chal-
lenging research question about disease improvement 
and management, as well as interdisciplinary collabora-
tion ranging from epidemiology to basic clinical research.
Conclusion
We expect results from this and future research to help 
improve the health status and determine specific bio-
logical pathways or treatments for health care services 
planning and management decisions. Ultimately, this 
information will help policy-makers and public health 
decision-makers develop policies to improve the diagno-
sis, management and control of COPD. A biobank that 
has been designed to store blood, nail, hair and urine 
samples for future research is another strength of this 
study. Researchers who are interested in using the infor-
mation can refer to the following web page: http:// persi 
ancoh ort. com.
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